Xultophy

Generic name: insulin degludec and liraglutide

Used for: Type 2 diabetes

How do you pay?

How to pay the least

Ask for the cash price

Xultophy

Xultophy is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Xultophy’s cash price, and one or two other pharmacies too.

Free from the maker, if you qualify Novo Nordisk Patient Assistance Program (PAP). For all other medications, total household income must be at or below 400% of the federal poverty level. Or call 1-866-310-7549.

See if you qualify 

Compare every option

Question
Brand nameXultophy
Authorized genericinsulin degludec and liraglutide
Regular genericinsulin degludec and liraglutide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Xultophy?
The original
–
–

Coverage: With Medicare, a month’s supply of a covered insulin costs no more than $35.

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Xultophy’s maker. Ask the pharmacy for Xultophy’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Xultophy itself, from the same company, sold without the brand name, and usually for less. For now Xultophy is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Xultophy is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Xultophy’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

XULTOPHY 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

  • Coadministration with any other product containing liraglutide or another GLP-1 receptor agonist is not recommended.
  • Not recommended for the treatment of diabetic ketoacidosis.
  • Has not been studied in combination with prandial insulin.

Source: the FDA label for Xultophy (Novo Nordisk), October 14, 2025. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/xultophy/